ASH 2023 | Catheter-based therapy in patients with cancer-associated intermediate/high-risk pulmonary embolism

Orly Leiva, MD, NYU Langone Health, New York City, NY, discusses the underrepresentation of cancer patients in device trials and cardiology, emphasizing a need for including these patients in order to understand the outcomes associated with catheter-based therapy (such as catheter-directed thrombolysis and percutaneous mechanical thrombectomy) for pulmonary embolism (PE). In a retrospective study, Dr Leiva and his team used data from a national registry to investigate the clinical outcomes of patients with a history of cancer who were admitted to hospital for treated intermediate- or high-risk PE and treated with or without catheter-based therapy. The analysis found that these invasive interventions decreased hospital mortality and hospital readmission in this vulnerable patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.